Literature DB >> 23295237

Bladder cancer in 2012: Challenging current paradigms.

Aidan P Noon1, James W F Catto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23295237     DOI： 10.1038/nrurol.2012.252

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.

Authors:  Savino M Di Stasi; Marco Valenti; Cristian Verri; Emanuele Liberati; Arcangelo Giurioli; Gioia Leprini; Francesco Masedu; Antonio R Ricci; Francesco Micali; Giuseppe Vespasiani
Journal:  Lancet Oncol       Date:  2011-08-08       Impact factor: 41.316

2.  Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.

Authors:  Ronac Mamtani; Kevin Haynes; Warren B Bilker; David J Vaughn; Brian L Strom; Karen Glanz; James D Lewis
Journal:  J Natl Cancer Inst       Date:  2012-08-09       Impact factor: 13.506

3.  Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

Authors:  Joaquim Bellmunt; Hans von der Maase; Graham M Mead; Iwona Skoneczna; Maria De Santis; Gedske Daugaard; Andreas Boehle; Christine Chevreau; Luis Paz-Ares; Leslie R Laufman; Eric Winquist; Derek Raghavan; Sandrine Marreaud; Sandra Collette; Richard Sylvester; Ronald de Wit
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

4.  Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

Authors:  Andrea Necchi; Luigi Mariani; Nadia Zaffaroni; Lawrence H Schwartz; Patrizia Giannatempo; Flavio Crippa; Carlo Morosi; Rodolfo Lanocita; Teodoro Sava; Cinzia Ortega; Caterina Messina; Cosimo Sacco; Marzia Pennati; Maria G Daidone; Nicola Nicolai; Filippo De Braud; Alessandro M Gianni; Roberto Salvioni
Journal:  Lancet Oncol       Date:  2012-07-20       Impact factor: 41.316

5.  Long-term impact of arsenic in drinking water on bladder cancer health care and mortality rates 20 years after end of exposure.

Authors:  Mario I Fernández; J Francisco López; Bruno Vivaldi; Fernando Coz
Journal:  J Urol       Date:  2012-01-15       Impact factor: 7.450

6.  A new and highly prognostic system to discern T1 bladder cancer substage.

Authors:  Bas W G van Rhijn; Theo H van der Kwast; Sultan S Alkhateeb; Neil E Fleshner; Geert J L H van Leenders; Peter J Bostrom; Madelon N M van der Aa; David M Kakiashvili; Chris H Bangma; Michael A S Jewett; Alexandre R Zlotta
Journal:  Eur Urol       Date:  2011-10-25       Impact factor: 20.096

7.  Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study.

Authors:  Renzo Colombo; Lorenzo Rocchini; Nazareno Suardi; Fabio Benigni; Giorgia Colciago; Arianna Bettiga; Federico Pellucchi; Carmen Maccagnano; Alberto Briganti; Andrea Salonia; Patrizio Rigatti; Francesco Montorsi
Journal:  Eur Urol       Date:  2012-05-18       Impact factor: 20.096

8.  Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.

Authors:  Nicholas D James; Syed A Hussain; Emma Hall; Peter Jenkins; Jean Tremlett; Christine Rawlings; Malcolm Crundwell; Bruce Sizer; Thiagarajan Sreenivasan; Carey Hendron; Rebecca Lewis; Rachel Waters; Robert A Huddart
Journal:  N Engl J Med       Date:  2012-04-19       Impact factor: 91.245

9.  Genome sequencing identifies a basis for everolimus sensitivity.

Authors:  Gopa Iyer; Aphrothiti J Hanrahan; Matthew I Milowsky; Hikmat Al-Ahmadie; Sasinya N Scott; Manickam Janakiraman; Mono Pirun; Chris Sander; Nicholas D Socci; Irina Ostrovnaya; Agnes Viale; Adriana Heguy; Luke Peng; Timothy A Chan; Bernard Bochner; Dean F Bajorin; Michael F Berger; Barry S Taylor; David B Solit
Journal:  Science       Date:  2012-08-23       Impact factor: 47.728

10.  Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial.

Authors:  Rianne J M Lammers; Wim P J Witjes; Maria H D Janzing-Pastors; Christien T M Caris; J Alfred Witjes
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544
  10 in total
  11 in total

1.  Bladder cancer: Progress in defining progression in NMIBC.

Authors:  Michael Gierth; Maximilian Burger
Journal:  Nat Rev Urol       Date:  2013-11-26       Impact factor: 14.432

2.  Will the 40-gene expression classifier predict responders to EGFR targeted chemotherapy for the invasive bladder cancer patients?

Authors:  Jayoung Kim; Wun-Jae Kim
Journal:  Ann Transl Med       Date:  2015-02

3.  Regulation of metastasis of bladder cancer cells through the WNT signaling pathway.

Authors:  Yiheng Du; Yongchuan Wang; Fei Zhang; Wenbo Wu; Wei Wang; Hao Li; Shujie Xia; Haitao Liu
Journal:  Tumour Biol       Date:  2015-06-12

4.  Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism.

Authors:  Austin Yeon; Sungyong You; Minhyung Kim; Amit Gupta; Myung Hee Park; Daniel J Weisenberger; Gangning Liang; Jayoung Kim
Journal:  Theranostics       Date:  2018-08-10       Impact factor: 11.600

5.  The c-MET Network as Novel Prognostic Marker for Predicting Bladder Cancer Patients with an Increased Risk of Developing Aggressive Disease.

Authors:  Young-Won Kim; Seok Joong Yun; Phildu Jeong; Seon-Kyu Kim; Seon-Young Kim; Chunri Yan; Sung Phil Seo; Sang Keun Lee; Jayoung Kim; Wun-Jae Kim
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

6.  Assess the expression of ubiquitin specific protease USP2a for bladder cancer diagnosis.

Authors:  Pildu Jeong; Yun-Sok Ha; Seok-Joong Yun; Hyung Yoon Yoon; Michael R Freeman; Jayoung Kim; Wun-Jae Kim
Journal:  BMC Urol       Date:  2015-08-07       Impact factor: 2.264

Review 7.  Urinary proteomics and metabolomics studies to monitor bladder health and urological diseases.

Authors:  Zhaohui Chen; Jayoung Kim
Journal:  BMC Urol       Date:  2016-03-22       Impact factor: 2.264

8.  Regulator of cullins-1 expression knockdown suppresses the malignant progression of muscle-invasive transitional cell carcinoma by regulating mTOR/DEPTOR pathway.

Authors:  W Wang; H Chen; Z Liu; P Qu; J Lan; H Chen; L Zou; J Qiu
Journal:  Br J Cancer       Date:  2016-01-07       Impact factor: 7.640

9.  Targeting antisense mitochondrial noncoding RNAs induces bladder cancer cell death and inhibition of tumor growth through reduction of survival and invasion factors.

Authors:  Vincenzo Borgna; Lorena Lobos-González; Francisca Guevara; Eduardo Landerer; Maximiliano Bendek; Rodolfo Ávila; Verónica Silva; Claudio Villota; Mariela Araya; Alexis Rivas; Constanza López; Teresa Socias; Jorge Castillo; Luis Alarcón; Luis O Burzio; Verónica A Burzio; Jaime Villegas
Journal:  J Cancer       Date:  2020-01-17       Impact factor: 4.207

10.  S-Palmitoylation as a Functional Regulator of Proteins Associated with Cisplatin Resistance in Bladder Cancer.

Authors:  Muhammad Shahid; Minhyung Kim; Peng Jin; Bo Zhou; Yang Wang; Wei Yang; Sungyong You; Jayoung Kim
Journal:  Int J Biol Sci       Date:  2020-07-19       Impact factor: 6.580
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.